Medarex, Inc. - Financial and Strategic Analysis ReviewSummaryMedarex, Inc. (Medarex) is a biopharmaceutical company focused on the development and commercialization of fully therapeutic products in the therapeutic areas of oncology, inflammation, autoimmune disorders and infectious diseases. Medarex's UltiMAb technology is used in product development. With the use of the technology, Medarex is generating, supporting and commercializing number of fully human antibody drugs. Medarex has a wide product pipeline of 34 antibodies obtained from Medarex technology, with six product candidates in phase III clinical trials. In addition, the company has several product candidates in pre-clinical development.Global Markets Direct, the leading business information provider, presents an in-depth business, strategic and financial analysis of Medarex, Inc.. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis and Global Markets Direct's views on the company.Scope' The company's strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational factors are considered. ' The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are highlighted. ' The report contains critical company information ' business structure and operations, the company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries.' It provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters.' Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.Reasons to buy' A quick 'one-stop-shop' to understand the company. ' Enhance business/sales activities by understanding customers' businesses better.' Get detailed information and financial & strategic analysis on companies operating in your industry.' Identify prospective partners and suppliers ' with key data on their businesses and locations.' Capitalize on competitors' weaknesses and target the market opportunities available to them.' Compare your company's financial trends with those of your peers / competitors.' Scout for potential acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Medarex, Inc. - Financial and Strategic Analysis Review
Published on February 2009
Report Summary
Medarex, Inc. - Financial and Strategic Analysis Review
Summary
Medarex, Inc. (Medarex) is a biopharmaceutical company focused on the development and commercialization of fully therapeutic
products in the therapeutic areas of oncology, inflammation, autoimmune disorders and infectious diseases. Medarex's UltiMAb
technology is used in product development. With the use of the technology, Medarex is generating, supporting and commercializing
number of fully human antibody drugs. Medarex has a wide product pipeline of 34 antibodies obtained from Medarex
technology, with six product candidates in phase III clinical trials. In addition, the company has several product candidates in
pre-clinical development.
Global Markets Direct, the leading business information provider, presents an in-depth business, strategic and financial analysis of
Medarex, Inc.. The report provides a comprehensive insight into the company, including business structure and operations, executive
biographies and key competitors. The hallmark of the report is the detailed strategic analysis and Global Markets Direct's views on the
company.
Scope
' The company's strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational
factors are considered.
' The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are
highlighted.
' The report contains critical company information ' business structure and operations, the company history, major products and
services, key competitors, key employees and executive biographies, different locations and important subsidiaries.
' It provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters.
' Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Reasons to buy
' A quick 'one-stop-shop' to understand the company.
' Enhance business/sales activities by understanding customers' businesses better.
' Get detailed information and financial & strategic analysis on companies operating in your industry.
' Identify prospective partners and suppliers ' with key data on their businesses and locations.
' Capitalize on competitors' weaknesses and target the market opportunities available to them.
' Compare your company's financial trends with those of your peers / competitors.
' Scout for potential acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Medarex, Inc. - Financial and Strategic Analysis Review Page 1/5

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Table of Content
Table Of Contents
Key Information 1
Key Ratios 1
Share Data 1
Performance Chart 1
Key Facts 3
Major Products and Services 4
Overview 4
History 5
SWOT Analysis Overview 6
Overview 6
Medarex, Inc. - Strengths 6
Intellectual Property 6
Ipilimumab 6
UltiMAb Technology 6
Medarex, Inc. - Weaknesses 6
Continuous Net Losses 6
Negative Impact of Equity Stake in Celldex 6
Dependence on the Contract Agreements for Commercialization 6
Medarex, Inc. - Opportunities 6
Growing Cancer Market 6
Milestone Payments 7
Collaboration with BioWa, Inc. 7
Emerging Markets 7
Medarex, Inc. - Threats 7
Reimbursement and Pricing Controls 7
Intense Competition and Rapid Technological Changes 7
Pending Litigations 7
Tightening of the FDA's Regulatory Oversight 7
Impact of the Financial Crisis 7
Industry Consolidation 8
Key Competitors 8
Key Employees 8
Company Statement 9
Locations And Subsidiaries 10
Head Office 10
Other Locations & Subsidiaries 10
Financial Ratios 11
Capital Market Ratios 11
Annual Ratios 12
Interim Ratios 13
Ratio Charts 14
Appendix 15
Methodology 15
Ratio Definitions 15
Medarex, Inc. - Financial and Strategic Analysis Review Page 2/5

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
About Global Markets Direct 18
Contact Us 18
Disclaimer 18
List of Tables
Medarex, Inc., Key Facts, 2006 1
Medarex, Inc., Key Ratios 1
Medarex, Inc., Share Data 1
Medarex, Inc., Key Facts 3
Major Products and Services 4
Medarex, Inc., History 5
Currency Codes 15
Capital Market Ratios 15
Equity Ratios 16
These ratios are based on per share value. 16
Profitability Ratios 16
Cost Ratios 17
Liquidity Ratios 17
Leverage Ratios 17
Efficiency Ratios 18
List of Figures
Medarex, Inc., Performance Chart (2003 - 2007) 1
Medarex, Inc., Ratio Charts 14
Medarex, Inc. - Financial and Strategic Analysis Review Page 3/5

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Medarex, Inc. - Financial and Strategic Analysis Review
Product Formats
Please select the product formats and the quantity you require.
Digital Copy--USD 125.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Medarex, Inc. - Financial and Strategic Analysis Review Page 4/5

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Medarex, Inc. - Financial and Strategic Analysis Review Page 5/5